Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nova Eye Medical ( (AU:EYE) ) has issued an update.
Nova Eye Medical has scheduled an investor webinar for Monday, 2 February 2026 at 11:30 am AEDT, where Managing Director Tom Spurling will present the company’s quarterly results and provide an update on the iTrack Registry. Shareholders and interested investors can register online and will be able to submit questions ahead of time or participate in a live Q&A during the session, signalling the company’s continued engagement with its investor base and providing greater transparency around the performance and clinical uptake of its glaucoma treatment technologies.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company specialising in ophthalmic treatment technologies and devices for glaucoma care. Its portfolio includes the iTrack Advance minimally invasive glaucoma surgical device, designed to restore the eye’s natural outflow pathway and reduce reliance on anti-glaucoma medications in mild to moderate glaucoma, and the Molteno3 glaucoma drainage device platform for long-term intraocular pressure control in severe glaucoma cases. The company sells its products globally through a network of distribution partners, with sales headquarters in Fremont, California, and manufacturing facilities in California and Dunedin, New Zealand.
Average Trading Volume: 423,348
Technical Sentiment Signal: Buy
Current Market Cap: A$54.12M
For detailed information about EYE stock, go to TipRanks’ Stock Analysis page.